January 2005 in “Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München)” Topical immunotherapy with DPCP is most effective for certain alopecia areata types, with success linked to age and disease duration, and influenced by a gene polymorphism.
Cyproterone acetate is used for topical treatment of diseases dependent on male hormones.
50 citations
,
January 1941 in “Annals of Internal Medicine” Idiopathic hypoparathyroidism is rare and can be managed with dihydrotachysterol.
December 2025 in “VNU Journal of Science Medical and Pharmaceutical Sciences” PRP therapy is effective and safe for skin conditions like wound healing and hair loss.
7 citations
,
September 2019 in “European Journal of Case Reports in Internal Medicine” Linagliptin may cause hair loss and skin blisters.
Platycladi Cacumen may help treat hair loss by targeting specific proteins and pathways.
Platelet-rich plasma (PRP) can help with hair loss and improve hair transplant results.
1 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Farudodstat may effectively treat alopecia areata without harmful side effects.
4 citations
,
January 2024 in “Allergy” Everyone has an immune response to PPD, but reactions differ, causing tolerance, mild inflammation, or allergy.
Lichen planus commonly affects middle-aged adults, often involves limbs and mucosal areas, and can be linked to immune diseases.
348 citations
,
July 2017 in “Skin appendage disorders” Platelet-rich plasma shows promise for skin and hair treatments but needs more research and standardization.
1 citations
,
June 2024 in “British Journal of Dermatology” Mycophenolate mofetil effectively improved skin pigmentation and itching in a woman with lichen planus pigmentosus and frontal fibrosing alopecia.
11 citations
,
January 2010 in “European Journal of Dermatology” Contact immunotherapy helped hair regrow in a patient with both alopecia and psoriasis.
May 2024 in “News Digital Object Group” PRP may help with hair loss, but more research is needed.
January 2019 in “Egyptian Journal of Dermatology and Venereology /Egyptian Journal of Dermatology and Venerology” Mixing calcipotriol with a steroid is almost as effective as using a steroid alone for alopecia areata and has fewer side effects.
5 citations
,
January 2016 in “European Journal of Dermatology” Suplatast tosilate successfully treated a woman's systemic sclerosis symptoms.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
1 citations
,
August 2020 in “Journal of The American Academy of Dermatology” The authors agree that standardizing how PRP methods are reported could help compare results, but note that the link between PRP's contents and hair growth is unclear, and recommend avoiding split-scalp designs in future trials.
September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
April 2026 in “Diagnostics” Parry–Romberg Syndrome can involve the brain even without obvious symptoms, and a new diagnostic framework is suggested for early detection.
87 citations
,
December 2016 in “British journal of dermatology/British journal of dermatology, Supplement” Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.
37 citations
,
February 2007 in “Experimental Dermatology” Increasing PDCD4 protein may help prevent or treat some skin cancers.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
June 2026 in “Frontiers in Immunology” This case report highlights the successful use of upadacitinib, a selective JAK1 inhibitor, in treating a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata, conditions that share the JAK-STAT signaling pathway. Conventional therapies had failed, but upadacitinib (15 mg daily) led to rapid improvement: pruritus subsided within days, AD-related erythema cleared by 15 weeks, complete eyebrow regrowth occurred within months, and significant vitiligo repigmentation was observed at one year. The treatment was well-tolerated, suggesting that upadacitinib monotherapy could be an effective and well-tolerated option for these co-existing conditions, supporting a "multi-disease therapy" approach targeting common pathogenic pathways.
13 citations
,
January 2012 in “Case reports in dermatological medicine” An 84-year-old man got a rare scalp condition from using imiquimod cream, which was cured with systemic steroids.